Identifying extra-nuclear factors that control the production of cannabidiol

特鲁多政府计划“合法化，规范和限制大麻的获取”。然而，这种植物产生的药物化学品（大麻素和萜烯）的安全药用也必须植根于对最佳实践的科学理解。尽管种植了数千年，但医用大麻在现代科学研究项目中基本上没有出现。因此，关于治疗益处的声明和如何生产药物化合物（大麻素）的知识落后于允许在加拿大使用医用大麻的立法。这限制了像First Access Medical这样的公司开发工业规模的工艺，这些工艺可以可靠地从植物中生产特定的大麻素。我们的研究旨在为控制一种关键大麻素大麻二酚生产的分子实体提供新的知识。为此，我们将比较蛋白质和转录的DNA图谱的大麻品种，产生大量和少量的大麻二酚。我们还将创建数学模型，将预测的大麻二酚含量高和低的品种与精心设计的植物育种计划中的品种进行比较。这些新知识将使FAM能够销售新产品，提高其市场竞争力，为患者保持高质量和标准化的药物，预测实际产量，并评估临床应用。这项研究将加速知识产权的发展，从而为FAM创造新的收入来源。可预测地生产大麻素（治疗产品中的活性成分）的能力可能对加拿大具有深远的医学和经济意义。

The Trudeau government plans to "legalize, regulate, and restrict access to marijuana". However, safe medicinal use of the pharmaceutical chemicals produced by this plant (cannabinoids and terpenes) must also be rooted in a scientific understanding of best practices. Despite cultivation for millennia, medical marijuana has been largely absent from modern scientific research programs. Therefore claims of therapeutic benefits and knowledge of how to produce the pharmaceutical compounds (cannabinoids) lags behind the legislation that allows medical marijuana use in Canada. This limits companies, like First Access Medical, in their development of industrial scale processes that reliably produce particular cannabinoids from plants. Our research proposes to contribute new knowledge of the molecular entities that control the production of one key cannabinoid, cannabidiol. To this end, we will compare protein and transcribed DNA profiles of marijuana cultivars that produce cannabidiol in high and low quantities. We will also create mathematical models that compare predicted cannabidiol profiles of cultivars with high and low quantities to those created in a careful plant breeding program. This new knowledge will allow FAM to sell new products, increase their market competitiveness and maintain high quality and standardized drugs for patients, predict practical yields, and evaluate clinical applications. This research will accelerate intellectual property development and thus create a new revenue stream for FAM. The capacity to predictably produce cannabinoids, the active ingredients in therapeutic products, could have profound medicinal and economic importance to Canada.